title: Salivary transcriptomic biomarkers for detection of ovarian cancer: for serous papillary adenocarcinoma.
abstract: Ovarian cancer is the most lethal gynecological cancer due to lack of clear symptom and reliable screening biomarker in the early stage. The capability to detect the initiation of malignancy with a sensitive and effective approach is one of the most desirable goals for ovarian cancer therapy. In this study, we spearheaded noninvasive detection of ovarian cancer by salivary transcriptomic biomarkers, and evaluated the clinical utilities of discovered biomarkers using a clinical case-control study. To find salivary mRNA biomarkers, salivary transcriptomes in 11 ovarian cancer patients and 11 matched controls were profiled by Affymetrix HG-U133-Plus-2.0 array. The biomarker candidates selected from the microarray results were then subjected to clinical validation by RT-qPCR using an independent sample cohort including 21 ovarian cancer patients and 35 healthy controls. Seven downregulated mRNA biomarkers were validated. The logistic regression model revealed the combination of five validated biomarkers (AGPAT1, B2M, BASP2, IER3, and IL1B) can significantly discriminate ovarian cancer patients (n = 21) from the healthy controls (n = 35), yielding a receiver operating characteristic plot, area under the curve value of 0.909 with 85.7% sensitivity and 91.4% specificity. In summary, we have demonstrated that the RNA signatures in saliva could serve as biomarkers for detection of ovarian cancer with high sensitivity and specificity. This emerging approach with high-throughput, noninvasive, and effective advantages provides a feasible means for detection of systemic cancer, and opens a new avenue for early disease detection.
authors.affiliation: Graduate Institute of Biomedical Engineering, National Central University, Jhongli City, Taiwan, Republic of China.
authors.forename: Yu-Hsiang
authors.initials: YH
authors.lastname: Lee
authors.forename: Jae Hoon
authors.initials: JH
authors.lastname: Kim
authors.forename: Hui
authors.initials: H
authors.lastname: Zhou
authors.forename: Bo Wook
authors.initials: BW
authors.lastname: Kim
authors.forename: David T
authors.initials: DT
authors.lastname: Wong
mesh_terms: D000231:Adenocarcinoma, Papillary / Q000175:diagnosis* / Q000235:genetics; D000328:Adult; D000368:Aged; D014408:Biomarkers, Tumor / Q000032:analysis / Q000235:genetics*; D005260:Female; D020869:Gene Expression Profiling / Q000379:methods*; D015972:Gene Expression Regulation, Neoplastic; D006801:Humans; D008875:Middle Aged; D008954:Models, Biological; D010051:Ovarian Neoplasms / Q000175:diagnosis* / Q000235:genetics; D012333:RNA, Messenger / Q000235:genetics; D012463:Saliva / Q000378:metabolism*; D012680:Sensitivity and Specificity; D059467:Transcriptome
chemical_list: D014408:Biomarkers, Tumor; D012333:RNA, Messenger
references.citation: Mol Cell Biol. 2004 Jan;24(2):537-49
references.pmid: 14701728
references.citation: Gastroenterology. 2010 Mar;138(3):949-57.e1-7
references.pmid: 19931263
references.citation: Acta Endocrinol (Copenh). 1986 Aug;112(4):603-8
references.pmid: 3751467
references.citation: Cancer Biol Ther. 2009 Dec;8(24):2323-8
references.pmid: 19829086
references.citation: Gynecol Oncol. 2010 May;117(2):159-69
references.pmid: 20181382
references.citation: Clin Chem. 1993 Apr;39(4):561-77
references.pmid: 8472349
references.citation: Cancer Res. 2011 Apr 15;71(8):3162-72
references.pmid: 21289131
references.citation: Trans Am Clin Climatol Assoc. 2004;115:233-47; discussion 247-8
references.pmid: 17060970
references.citation: Lancet. 2002 Feb 16;359(9306):572-7
references.pmid: 11867112
references.citation: J Immunol. 1987 Jan 15;138(2):435-9
references.pmid: 3794339
references.citation: Clin Cancer Res. 2009 Sep 1;15(17):5473-7
references.pmid: 19706812
references.citation: PLoS One. 2010 Dec 31;5(12):e15573
references.pmid: 21217834
references.citation: Clin Chem. 2009 Apr;55(4):611-22
references.pmid: 19246619
references.citation: J Proteome Res. 2009 Jan;8(1):239-45
references.pmid: 19118452
references.citation: Cancer Metastasis Rev. 2011 Mar;30(1):141-51
references.pmid: 21298574
references.citation: J Dent Res. 2004 Mar;83(3):199-203
references.pmid: 14981119
references.citation: Clin Cancer Res. 2006 May 1;12(9):2788-94
references.pmid: 16675572
references.citation: CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49
references.pmid: 19474385
references.citation: Eur J Cell Biol. 2011 Jun-Jul;90(6-7):545-52
references.pmid: 21112119
references.citation: Eur J Cancer. 2001 Dec;37(18):2357-64
references.pmid: 11720828
references.citation: Obstet Gynecol. 1990 Apr;75(4):701-4
references.pmid: 2179784
references.citation: Arthritis Rheum. 2007 Nov;56(11):3588-600
references.pmid: 17968930
references.citation: Clin Cancer Res. 2004 Dec 15;10(24):8442-50
references.pmid: 15623624
references.citation: Tumour Biol. 2010 Jun;31(3):209-15
references.pmid: 20393825
references.citation: Mol Cancer Ther. 2008 Jan;7(1):27-37
references.pmid: 18187805
references.citation: J Natl Cancer Inst. 2008 Oct 15;100(20):1432-8
references.pmid: 18840817
references.citation: Experientia. 1976;32(7):940-1
references.pmid: 954994
references.citation: Cancer. 2001 Dec 1;92(11):2837-44
references.pmid: 11753957
references.citation: Semin Cancer Biol. 1999 Apr;9(2):117-24
references.pmid: 10202133
references.citation: Gynecol Oncol. 2004 Dec;95(3):672-9
references.pmid: 15581980
references.citation: Clin Cancer Res. 2007 Feb 15;13(4):1350; author reply 1351
references.pmid: 17317848
references.citation: J Clin Oncol. 2006 Apr 10;24(11):1754-60
references.pmid: 16505414
references.citation: Zentralbl Gynakol. 1992;114(1):6-9
references.pmid: 1585745
references.citation: PLoS One. 2009 Jun 11;4(6):e5875
references.pmid: 19517020